{"id":"W4386705026","doi":"10.1530/erc-22-0301","title":"A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors","year":2023,"lang":"en","type":"article","venue":"Endocrine Related Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Pfizer; Eli Lilly and Company","keywords":"Temsirolimus; Bevacizumab; Medicine; Discontinuation; Adverse effect; Internal medicine; Regimen; Phases of clinical research; Clinical endpoint; Gastroenterology; Progression-free survival; Oncology; Surgery; Toxicity; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002239766,0.0009605662,0.002145899,0.0003463256,0.0002765101,0.0005894714,0.0006020726,0.0006895764,0.001175773],"category_scores_gemma":[0.000744351,0.0005233223,0.000868031,0.0003672507,0.0005334007,0.0005108701,0.0003238129,0.002264361,0.0003169789],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005351647,"about_ca_system_score_gemma":0.001526062,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005785688,"about_ca_topic_score_gemma":0.002053854,"domain_scores_codex":[0.999292,0.0004176016,0.00004653401,0.00009166555,0.00007222685,0.00007987536],"domain_scores_gemma":[0.9992151,0.00013628,0.0001223862,0.00004441616,0.00004532779,0.0004364487],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4848008,0.1204384,0.01850827,0.001150464,0.002636032,0.0007548406,0.0003668917,0.003076236,0.1559624,0.0003580085,0.002760353,0.2091871],"study_design_scores_gemma":[0.456182,0.5197021,0.01334943,0.00002872956,0.0005629746,0.0004449482,0.00004172758,0.001889432,0.005010393,0.0001102822,0.002649817,0.00002812593],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937868,0.002728056,0.0008095505,0.0002640864,0.000108158,0.001387338,0.0002202332,0.00004593257,0.0006499173],"genre_scores_gemma":[0.9900468,0.001929202,0.003317168,0.0006516963,0.0002001109,0.001703387,0.001217578,0.00001962444,0.0009143533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002239766,"threshold_uncertainty_score":0.01184517,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02371539306775024,"score_gpt":0.3639791544733013,"score_spread":0.3402637614055511,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}